When to Stop Breast Cancer Screening
Age-Based Recommendations for Stopping Breast Cancer Screening
- The American College of Physicians recommends discontinuing screening mammography in average-risk women aged 75 years or older 1, 2
- The American Cancer Society recommends continuing screening mammography as long as a woman's overall health is good and she has a life expectancy of 10 or more years 3, 4
- Most guidelines suggest discontinuing screening when a woman is unlikely to have a life expectancy long enough to benefit from screening—typically 10 years 1, 2
Rationale for Stopping Screening at Age 75 or with Limited Life Expectancy
Time to Benefit Considerations
- It takes an average of almost 11 years before 1 death from breast cancer is prevented for every 1000 women screened 2
- The long time lag between mammography and reduction in breast cancer mortality means women with shorter life expectancy are unlikely to benefit 2
Risk-Benefit Analysis
- Older women face a higher probability of developing and dying from breast cancer but also have a greater chance of dying from other causes 5, 1
- As women age, the potential harms of screening, such as false positives, overdiagnosis, unnecessary biopsies, and overtreatment, may outweigh the benefits 1
- Women with comorbid conditions that limit life expectancy are unlikely to benefit from screening 1, 2
Life Expectancy Considerations
- Among women aged 70 years with no comorbid conditions, average life expectancy is approximately 19 years 2
- Among women aged 75 years with no comorbid conditions, average life expectancy is approximately 15 years 2
- Among 70-year-old women with serious comorbid conditions, average life expectancy is approximately 11 years 2
- Among 75-year-old women with serious comorbid conditions, average life expectancy is approximately 9 years 2
Decision-Making Algorithm for Stopping Breast Cancer Screening
- If patient is ≥75 years old, consider discontinuing screening 1, 2
- If life expectancy is ≤10 years, discontinue screening 3, 4, 2
- Serious conditions like end-stage renal disease, severe heart failure, dementia, or metastatic cancer should be considered when assessing comorbidities 1, 2
Common Pitfalls in Decisions About Stopping Breast Cancer Screening
- The decision to discontinue screening should not be based solely on age but should incorporate health status and life expectancy 1, 2
- The mortality benefit of screening takes approximately 11 years to manifest, which may exceed life expectancy in elderly patients or those with significant comorbidities 2
- Older women are more susceptible to overdiagnosis and overtreatment of indolent cancers that would never become clinically significant in their lifetime 1
- As women age and develop new health conditions, the benefit-harm ratio of continued screening may change, requiring periodic reassessment 1, 2